v3.25.2
Segments - Schedule of Segment Reporting Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:            
Segment loss $ 45,592   $ 60,639   $ 104,527 $ 113,031
Reconciliation of segment loss            
Interest and other (income) expense, net (3,101)   (5,653)   (6,669) (11,535)
Interest expense 809   868   1,608 1,313
Net loss 43,300 $ 56,166 55,854 $ 46,955 99,466 102,809
Reportable Segment            
Operating expenses:            
Bexotegrast - clinical trial and third party contracting costs 13,359   26,360   34,948 43,577
Employee-related expenses - research and development (excluding stock-based compensation) 10,344   8,381   20,830 17,519
General and administrative costs (excluding stock-based compensation) 8,947   8,476   19,236 17,126
Other segment items 12,942   17,422   29,513 34,809
Segment loss 45,592   60,639   104,527 113,031
Reconciliation of segment loss            
Interest and other (income) expense, net (3,101)   (5,653)   (6,669) (11,535)
Interest expense 809   868   1,608 1,313
Net loss $ 43,300   $ 55,854   $ 99,466 $ 102,809